Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has initiated a strategic partnership with Flagship Pioneering, a life sciences innovation enterprise, to embark on a collaborative quest for groundbreaking obesity treatments in 2023. The alliance will tap into ProFound Therapeutics’ proprietary technology platform, a Flagship-founded entity, to bolster Pfizer’s research and development efforts in the weight management space. Pfizer has been granted the prerogative to progress promising therapeutic candidates identified through this collaboration.
Pfizer’s foray into obesity treatments is not new; according to the public data, the company’s pipeline already encompasses the GLP-1 receptor agonist danuglipron. This move follows Pfizer’s decision to discontinue the development of lotiglipron, another GLP-1 receptor agonist, earlier in the year.- Flcube.com
